|
[1]MOHD HANAFIAH K, GROEGER J, FLAXMAN AD, et al.Global epidemiology of hepatitis C virus infection:new estimates of age-specific antibody to HCV seroprevalence[J].Hepatology, 2013, 57 (4) :1333-1342.
|
|
[2]SIEVERT W, ALTRAIF I, RAZAVI HA, et al.A systematic review of hepatitis C virus epidemiology in asia, australia and egypt[J].Liver Int, 2011, 31 (Suppl 2) :61-80.
|
|
[3]DUAN Z, JIA JD, HOU J, et al.Current challenges and the management of chronic hepatitis C in mainland China[J].J Clin Gastroenterol, 2014, 48 (8) :679-686.
|
|
[4]RAO H, WEI L, LOPEZ-TALAVERA JC, et al.Distribution and clinical correlates of viral and host genotypes in chinese patients with chronic hepatitis C virus infection[J].J Gastroenterol Hepatol, 2014, 29 (3) :545-553.
|
|
[5]Chinese Society of Hepatology and Chinese Society of Infectious Disease, Chinese Medical Association.The guideline of prevention and treatment for hepatitis C:a 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1961-1979. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.丙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1961-1979.
|
|
[6]CHEN XY, SHANG J, YANG RF, et al.High sustained virological response to optimized therapy for refractory chronic hepatitis C treatment-na (i) ve patients:a multicenter randomized study[J].Chin J Hepatol, 2015, 23 (6) :412-417. (in Chinese) 陈新月, 尚佳, 杨瑞锋, 等.难治性慢性丙型肝炎初治患者优化治疗后的病毒学应答率研究[J].中华肝脏病杂志, 2015, 23 (6) :412-417.
|
|
[7]D'AMBROSIO R, AGHEMO A, RUMI MG, et al.A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis[J].Hepatology, 2012, 56 (2) :532-543.
|
|
[8]van der MEER AJ, VELDT BJ, FELD JJ, et al.Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis[J].JAMA, 2012, 308 (24) :2584-2593.
|
|
[9]HAGIHARA H, NOUSO K, KOBAYASHI Y, et al.Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma[J].Int J Clin Oncol, 2011, 16 (3) :210-220.
|
|
[10]LIU Z, WEI X, CHEN T, et al.Characterization of fibrosis changes in chronic hepatitis C patients after virological cure:a systematic review with meta-analysis[J].J Gastroenterol Hepatol, 2017, 32 (3) :548-557.
|
|
[11]WEI L, LI J, YANG X, et al.Nationwide survey of specialist knowledge on current standard of care (Peg-IFN/RBV) and barriers of care in chronic hepatitis C patients in China[J].J Gastroenterol Hepatol, 2016, 31 (12) :1995-2003.
|
|
[12]YU ML, YEH ML, TSAI PC, et al.Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C:a nationwide survey in Taiwan[J].Medicine (Baltimore) , 2015, 94 (13) :e690.
|
|
[13]BERTINO G, ARDIRI A, PROITI M, et al.Chronic hepatitis C:this and the new era of treatment[J].World J Hepatol, 2016, 8 (2) :92-106.
|
|
[14]SCHINAZI R, HALFON P, MARCELLIN P, et al.HCV directacting antiviral agents:the best interferon-free combinations[J].Liver Int, 2014, 34 (Suppl 1) :69-78.
|
|
[15]de CLERCQ E.Current race in the development of DAAs (directacting antivirals) against HCV[J].Biochem Pharmacol, 2014, 89 (4) :441-452.
|
|
[16]WEI L, ZHANG M, XU M, et al.A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin[J].J Gastroenterol Hepatol, 2016, 31 (11) :1860-1867.
|
|
[17]OMATA M, KANDA T, WEI L, et al.APASL consensus statements and recommendation on treatment of hepatitis C[J].Hepatol Int, 2016, 10 (5) :702-726.
|
|
[18]HNER ZU SIEDERDISSEN C, MAASOUMY B, MARRA F, et al.Drug-drug interactions with novel all oral interferon-free antiviral agents in a large real-world cohort[J].Clin Infect Dis, 2016, 62 (5) :561-567.
|
|
[19]Hepatitis C treatments containing sofosbuvir in combination with another direct acting antiviral drug:drug safety communication-serious slowing of heart rate when used with antiarrhythmic drug amiodarone[EB/OL].[2015-03-24].http://www.fda.gov/Safety/Med Watch/Safety Information/Safety Alertsfor Human Medical Products/ucm439662.htm.
|
|
[20]FDA Drug Safety Communication:FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie[EB/OL].[2015-10-22].http://www.fda.gov/Drugs/Drug Safety/ucm468634.htm&source=govdelivery&utm_medium=email&utm_source=govdelivery.
|
|
[21]Revisions of precautions (FY2016) [EB/OL].http://www.pmda.go.jp/english/safety/info-services/drugs/revision-of-precautions/0004.html.
|
|
[22]CONTI F, BUONFIGLIOLI F, SCUTERI A, et al.Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals[J].J Hepatol, 2016, 65 (4) :727-733.
|
|
[23]REIG M, MARIO Z, PERELLC, et al.Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy[J].J Hepatol, 2016, 65 (4) :719-726.
|
|
[24]CARDOSO H, VALE AM, RODRIGUES S, et al.High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis[J].J Hepatol, 2016, 65 (5) :1070-1071.
|
|
[25]WANG C, JI D, CHEN J, et al.Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents[J].Clin Gastroenterol Hepatol, 2017, 15 (1) :132-136.
|
|
[26]FDA Drug Safety Communication:FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C[EB/OL].[2016-10-04].http://www.fda.gov/drugs/drugsafety/ucm522932.htm.
|
|
[27]WANG C, LI B, CHEN J, et al.Hepatitis B reactivation after interferon-based therapy versus pan-oral direct acting antiviral agents in chronic hepatitis C patients co-infected with hepatitis B virus:a systematic review and meta-analysis[C].Boston:AASLD, 2016.
|
|
[28]HOOFNAGLE JH, SEEFF LB.Peginterferon and ribavirin for chronic hepatitis C[J].N Engl J Med, 2006, 355 (23) :2444-2451.
|
|
[29]YAN LB, RAO HY, MA YJ, et al.Hepatitis B virus infection in Chinese patients with hepatitis C virus infection:prevalence, clinical characteristics, viral interactions and host genotypes:a nationwide cross-sectional study[J].BMJ Open, 2016, 6 (10) :e012016.
|
|
[30]ISAACS A, LINDENMANN J.Virus interference.I.The interferon[J].Proc R Soc Lond B Biol Sci, 1957, 147 (927) :258-267.
|
|
[31]LINDAHL P, LEARY P, GRESSER I.Enhancement by interferon of the specific cytotoxicity of sensitized lymphocytes[J].Proc Natl Acad Sci U S A, 1972, 69 (3) :721-725.
|
|
[32]EINHORN S, STRANDER H.Is interferon tissue specific?-Effect of human leukocyte and fibroblast interferons on the growth of lymphoblastoid and osteosarcoma cell lines[J].J Gen Virol, 1977, 35 (3) :573-577.
|
|
[33]Expert Panel of Antiviral Therapy for Hepatocellular Carcinoma.Expert consensus on antiviral therapy to hepatitis B/C virus-related hepatocellular carcinoma[J].J Clin Hepatol, 2014, 30 (5) :390-395. (in Chinese) 肝细胞癌抗病毒治疗专家组.HBV/HCV相关性肝细胞癌抗病毒治疗专家共识[J].临床肝胆病杂志, 2014, 30 (5) :390-395.
|
|
[34]KAO JH, TUNG SY, LEE Y, et al.Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis[J].J Gastroenterol Hepatol, 2016, 31 (10) :1757-1765.
|
|
[35]LAWITZ E, MANGIA A, WYLES D, et al.Sofosbuvir for previously untreated chronic hepatitis C infection[J].N Engl J Med, 2013, 368 (20) :1878-87.
|
|
[36]WEI L, HAN T, YANG D, et al.Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-na6ve patients in China and South Korea[J].J Gastroenterol Hepatol, 2016, 31 (5) :912-920.
|
|
[37]WEI L.Makalu:twelve-week of treatment with ritonavir-boosted danoprevir plus peginterferon and ribavirin produces 96%SVR12 in HCV genotype 1-infected non-cirrhotic chinese patients[R].Shanghai:APASL, 2017.
|
|
[38]RUTTER K, HOFER H, BEINHARDT S, et al.Durability of SVR in chronic hepatitis C patients treated with peginterferon-α2a/ribavirin in combination with a direct-acting anti-viral[J].Aliment Pharmacol Ther, 2013, 38 (2) :118-123.
|
|
[39]BROGAN AJ, TALBIRD SE, THOMPSON JR, et al.Cost-effectiveness of Telaprevir combination therapy for chronic hepatitis C[J].PLo S One, 2014, 9 (3) :e90295.
|
DownLoad: